Stock ANNX ANNEXIN PHARMACEUTICALS AB
Add to a list
To use this feature you must be a member
Log inSign up

Annexin Pharmaceuticals AB Share Price

Equities

ANNX

SE0009664154

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 15:55:46 29/04/2024 BST 		5-day change 1st Jan Change
0.285 SEK -4.04% Intraday chart for Annexin Pharmaceuticals AB +5.17% +9.62%
04-12 Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-09 Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * - Sales 2025 * 39.6M 3.63M 289M Capitalization 103M 9.42M 750M
Net income 2024 * -52M -4.76M -379M Net income 2025 * -16M -1.46M -117M EV / Sales 2024 * -
Net cash position 2024 * 18.4M 1.68M 134M Net cash position 2025 * - 0 0 EV / Sales 2025 * 2.6 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 4
Yield 2024 *
-
Yield 2025 *
-
Free-Float 21.9%
More Fundamentals * Assessed data

Chart Annexin Pharmaceuticals AB

Dynamic Chart

Latest news about Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect CI
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US CI
Annexin Pharmaceuticals AB Announces First Patient Treated in the Second Dose Group in RVO Study CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Annexin Pharmaceuticals AB Announces Success in the Cancer Initiative CI
Annexin Pharmaceuticals AB Announces Promising Signals of Effect in RVO- Study CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Annexin Pharmaceuticals AB Auditor Raises 'Going Concern' Doubt CI
Annexin Reports First Imaging- Study Results in Retinal Vein Occlusion CI
Annexin Pharmaceuticals Names New Finance Chief MT
Annexin Pharmaceuticals AB Appoints Susanne Andersson as CFO CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
More news

Press releases Annexin Pharmaceuticals AB

Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns AQ
BioStock: Annexin towards completion of phase II study and share issue AQ
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward AQ
BioStock: Strong start for Annexin in 2024 AQ
Update on Annexin´s RVO study confirms promising signals of effect AQ
More press releases

News in other languages on Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB (publ) : le laboratoire dépose une demande d'essai clinique
More news

Quotes and Performance

1 day-4.04%
1 week+5.17%
Current month+14.00%
1 month+12.20%
3 months-0.35%
6 months-32.78%
Current year+9.62%
More quotes

Highs and lows

1 week
0.27
Extreme 0.265
0.32
1 month
0.23
Extreme 0.23
0.32
Current year
0.20
Extreme 0.203
0.32
1 year
0.20
Extreme 0.203
1.20
3 years
0.20
Extreme 0.203
2.35
5 years
0.20
Extreme 0.203
3.30
10 years
0.20
Extreme 0.203
13.20
More quotes

Managers and Directors - Annexin Pharmaceuticals AB

Managers TitleAgeSince
Anna Frostegård FOU
 Founder 51 31/12/13
Nils Anders Haegerstrand CEO
 Chief Executive Officer 63 31/12/17
Susanne Andersson DFI
 Director of Finance/CFO 53 10/04/23
Members of the board TitleAgeSince
Uli Alf Hacksell CHM
 Chairman 74 31/12/20
Mårten Österlund BRD
 Director/Board Member 67 31/12/20
Nils Anders Haegerstrand CEO
 Chief Executive Officer 63 31/12/17
More insiders

Quotes

Date Price Change Volume
29/04/24 0.285 -4.04% 172 145
26/04/24 0.297 +2.41% 397,407
25/04/24 0.29 +3.57% 778,465
24/04/24 0.28 +1.45% 4,010
23/04/24 0.276 +1.85% 56,737

Delayed Quote Nasdaq Stockholm, April 29, 2024 at 03:55 pm

More quotes

Company Profile

Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Company’s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.
Sector
Biotechnology & Medical Research
Calendar
14/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANNEXIN PHARMACEUTICALS AB Stock Annexin Pharmaceuticals AB
+9.62% 9.39M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.72% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.40% 95.28B
ARGENX SE Stock argenx SE
+1.46% 22.15B
BIONTECH SE Stock BioNTech SE
-15.90% 21.02B
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.01% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.03% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.36% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ANNX Stock